Company intelligence / Profile preview

New Amsterdam School

Naarden, Netherlandsnewamsterdamschool.org ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Obicetrapib, a novel oral CETP inhibitor, has demonstrated significant LDL-C lowering effects in high-risk cardiovascular patients on top of statins. In the BROOKLYN Phase 3 trial, it reduced LDL cholesterol by up to ~41% at one year versus placebo and showed a safety profile comparable to placebo. Additional late-stage trials are ongoing or recently completed, with topline data reported for several studies and regulatory filings anticipated[1][2][4].

Therapeutic areas: CardiovascularNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Menarini Group – exclusive licensing agreement for commercialization of obicetrapib in Europe

Beyond the preview

Go deeper on New Amsterdam School.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Amsterdam School.

Explore the full profile